Kilitch Drugs Updates Debt-to-Equity Conversion Terms for Material Subsidiary
Kilitch Drugs India Ltd 路 Outcome 路 13 Nov 2026, 12:25 am
Kilitch Drugs Updates Debt-to-Equity Conversion Terms for Material Subsidiary Kilitch Drugs (India) Limited issued a correction regarding its 22nd Oct'26 board approval to convert up to INR 57.00 crore of outstanding debt and service costs into equity of its material subsidiary, Kilitch Estro Biotech PLC. Due to a typographical error, the rectified acquisition price stands at INR 3,413.23 per share (previously INR 3,414), and the revised allotment is 1,66,471 equity shares (previously 1,66,472 shares). All other terms and conditions of the debt conversion remain unchanged.
Original exchange filing (PDF)
More announcements from Kilitch Drugs India Ltd
- We are submitting Scrutinizer''s Report for evoting of EGM 路 16 Nov 2026
- Proceeding of EGM held today i.e. 16th November, 2026 路 16 Nov 2026
- Intimation under regulation 30 of the SEBI LODR regulations 2015, corrigendum to the Notice of Extra Ordinary General Meeting 路 13 Nov 2026
- We are submitting herewith the outcome of the Board meeting 路 07 Nov 2026
- Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 07 Nov 2026
- Submitting unaudited financials results for quarter ended 30.09.2026 路 07 Nov 2026
- KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 06 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 06 Nov 2026
